Cell line · CVCL_1345
Papers68
1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.
1 to 20 of 68
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Kallikrein-Related Peptidase 5 Is Associated with Tumor Progression, KRT19 Expression, and Distinct Molecular Programs in High-Grade Serous Ovarian Cancer. | Cancers (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting Steroid-Metabolizing Enzymes with 15β-Substituted Estrone Analogues: Dual Discovery of AKR1C2/17β-HSD1 Inhibitors and a Fluorescent 17β-HSD1 Ligand. | Cancers (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| CCDC80 suppresses high-grade serous ovarian cancer migration via negative regulation of B7-H3. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Using targeted therapy to promote a pro-inflammatory tumour microenvironment and anti-tumour immune response in high grade serous ovarian cancer. | Br J Cancer | 2026 | Its Methods give the RRID and name the line | PubMed | |
| BMAL2 is a druggable target for ovarian clear cell carcinoma (OCCC). | EMBO Mol Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy. | Cell | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Tumor-Infiltrating Nociceptor Neurons in Ovarian Cancer Treatment Resistance. | Adv Biol (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Metabolome analysis identified exogenous cholesterol within lipid rafts that activate the Akt/mTOR signaling pathway in epithelial ovarian cancer. | Int J Cancer | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Keratin 19 as a prognostic marker and contributing factor of metastasis and chemoresistance in high-grade serous ovarian cancer. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Mesothelial cells promote peritoneal invasion and metastasis of ascites-derived ovarian cancer cells through spheroid formation. | Sci Adv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PARG regulates the proteasomal degradation of TARG1. | Cell Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Repurposing of ivacaftor shows potential to treat ROR1 expressing high-grade serous ovarian cancer. | Ther Adv Med Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Dynamic and Ongoing De Novo L1 Retrotransposition Contributes to Genome Plasticity and Intrapatient Heterogeneity in Ovarian Cancer. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PLK1 or WEE1 inhibition targets homologous recombination repair proficiency in BRCA1/2 wild-type high-grade serous ovarian cancer. | Cell Death Dis | 2025 | Its Methods give the RRID and name the line | PubMed | |
| SLC25A45 is required for mitochondrial uptake of methylated amino acids and de novo carnitine biosynthesis. | Mol Cell | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex. | Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Targeting of PTP4A3 overexpression sensitises HGSOC cells towards chemotherapeutic drugs. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Tumor clusters with divergent inflammation and human retroelement expression determine the clinical outcome of patients with serous ovarian cancer. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Targeting SUMOylation in ovarian cancer: Sensitivity, resistance, and the role of MYC. | iScience | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Systematic profiling of cancer-fibroblast interactions reveals drug combinations in ovarian cancer. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1345/papers